库尔肿瘤学公司COO在季度亏损中出售股票,但股票以强劲的收入和积极的分析家前景而上升。 Kura Oncology's COO sold shares amid quarterly loss, but stock rose on strong revenue and positive analyst outlook.

2025年11月14日, Kura肿瘤学首席操作官Kathleen Ford出售6 902股,每股11.18美元,将其股份减少6.15%至105 373股。 On November 14, 2025, Kura Oncology Chief Operating Officer Kathleen Ford sold 6,902 shares at $11.18 each, reducing her stake by 6.15% to 105,373 shares. 该公司报告的季度损失为每股0.85美元,估计缺失,尽管收入2 075万美元超过预测。 The company reported a quarterly loss of $0.85 per share, missing estimates, though revenue of $20.75 million exceeded forecasts. 由于分析师维持了“机动购买”共识和25.11美元的目标价格,大宗的股份升至11.20美元。 Shares rose to $11.20 on heavy volume, with analysts maintaining a "Moderate Buy" consensus and a $25.11 target price. 该公司继续开发小型分子癌症疗法,包括ziftomenib和titifarnib。 The company continues developing small molecule cancer therapies, including ziftomenib and tipifarnib.